Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial

NCT03003325 is registered in ClinicalTrials.gov with FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS as lead sponsor.

NCT NCT03003325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03003325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial
Lead sponsor
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Phase
Phase 2
Overall status
Completed
Start date
February 2, 2017
Completion date
March 31, 2023
Enrollment
127 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

polycythemia vera